Dezandrodeg (, ; developmental code names BMS-986365 and CC-94676) is an antiandrogen which is under development for the treatment of prostate cancer. It is taken orally. The drug acts as a dual androgen receptor antagonist and androgen receptor degrader. It is under development by Celgene Corporation and Bristol-Myers Squibb. As of June 2026, dezandrodeg is in phase 3 clinical trials for prostate cancer. It was also under development for the treatment of solid tumors, but no recent development has been reported.
See also List of investigational sex-hormonal agents
References